A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Atacicept (Primary)
- Indications IgA nephropathy; Proteinuria
- Focus Adverse reactions; Therapeutic Use
- Sponsors EMD Serono
- 28 Jun 2017 Planned End Date changed from 4 Feb 2020 to 17 Jan 2020.
- 30 May 2017 Planned End Date changed from 9 Oct 2019 to 4 Feb 2020.
- 14 Mar 2017 Planned number of patients changed from 100 to 30.